Technical Data
ICOS Ligand (CD275, Inducible T cell co-stimulator ligand, B7-H2, B7 homolog 2, B7-like protein Gl50, B7 related protein 1, B7H2, B7RP-1, B7RP1, GL50, ICOS LG , ICOSLG, KIAA0653, LICOS, Transmembrane protein B7 H2 ICOS ligand)
The inducible co-stimulator receptor (ICOS) is a member of the CD28 receptor family that is expressed on T cells. Recently, a new ligand (ICOS ligand, ICOSL) has been identified that binds to ICOS, but not to CD28 or CTLA-4. ICOSL is constitutively expressed on monocytes, dendritic cells and B cells. Binding of ICOSL delivers a co-stimulatory signal for T cell proliferation and cytokine secretion.

Suitable for use in Flow Cytometry and ELISA. It is expected that the antibody will be suited for all applications where recognition of the native protein is required. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1.2ug/10e6 cells
ELISA: 1:100-1:200
Optimal dilution determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG15E511Affinity Purified
50ug4C (-20C Glycerol)Blue IceHumanMouse
Human ICOSL extracellular domain (AF289028).
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, pH 7.2, 0.01% sodium azide, before the addition of glycerol to 40%.
Recognizes the extracellular domain of ICOSL transiently expressed on the cell surface of transfected BOSC cells as well as the native protein on antigen presenting cells (1).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Richter G, Het al., (2001) Tumor Necrosis Factor- Regulates the Expression of Inducible Costimulator Receptor Ligand on CD34+ Progenitor Cells during Differentiation into Antigen Presenting Cells. J. Biol. Chem. 276: 45686-45693. 2. Richter G, et al., al., Onkologie 27(1):91-5 3. Aicher A, et al., J. Immunol 1, 164(9):4689-96.